{"id":"W1764111892","doi":"10.1080/00325481.2015.998987","title":"Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis","year":2015,"lang":"en","type":"article","venue":"Postgraduate Medicine","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; PCSK9; Medicine; Evolocumab; Kexin; Placebo; Internal medicine; Adverse effect; Gastroenterology; Statin; Pharmacology; Endocrinology; Lipoprotein; Cholesterol; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0116465,0.001808004,0.005032562,0.001310133,0.0003411763,0.001673414,0.0007274575,0.001342072,0.002988456],"category_scores_gemma":[0.009017552,0.0008633199,0.009411767,0.001234674,0.0004339327,0.0008465359,0.0005475779,0.001097793,0.0005028261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009122029,"about_ca_system_score_gemma":0.001240618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007097492,"about_ca_topic_score_gemma":0.001136002,"domain_scores_codex":[0.9944056,0.003411905,0.0006910478,0.0006191265,0.0006836492,0.0001886371],"domain_scores_gemma":[0.9944839,0.002013249,0.002024911,0.0003077553,0.0008057012,0.0003645543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7034103,0.001710468,0.01567677,0.01194258,0.1726543,0.0001898876,0.0001651552,0.002432732,0.01288247,0.0001141029,0.002394721,0.07642651],"study_design_scores_gemma":[0.4155815,0.1536329,0.1054463,0.001373998,0.3067423,0.0007772028,0.0001399612,0.003575143,0.005148058,0.0003502354,0.007050473,0.0001820254],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8194344,0.1555358,0.007363867,0.0007601405,0.000455989,0.005217704,0.007215517,0.0002668008,0.00374978],"genre_scores_gemma":[0.9704052,0.01817622,0.002758671,0.0009312907,0.0003497001,0.001880898,0.004252128,0.00005998915,0.001185979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0116465,"threshold_uncertainty_score":0.06159329,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03230265787129456,"score_gpt":0.3366144563576577,"score_spread":0.3043117984863632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}